Merck Press Releases

Published on October 24, 2013 - 12:50 GMT

The Merck Manual Go-To Home Guide for Symptoms Helps Patients Assess When to Worry and When to Wait, Determine Next Steps

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the availability of a newly published book, The Merck Manual Go-To Home Guide for Symptoms, which offers essential information on when to seek medical attention and when …

Distribution channels: Companies

Published on October 23, 2013 - 17:31 GMT

Merck Receives Breakthrough Therapy Designation for MK-5172/MK-8742, an Investigational Oral Combination Regimen for the Treatment ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has granted MK-5172/MK-8742 Breakthrough Therapy designation for treatment of …

Distribution channels: Companies

Published on October 23, 2013 - 17:30 GMT

ZOSTAVAX® (Zoster Vaccine Live) Awarded Prix Galien USA 2013 Best Biotechnology Product

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that ZOSTAVAX® (Zoster Vaccine Live), the company's vaccine to help prevent shingles, received the Prix Galien USA 2013 …

Distribution channels: Companies

Published on October 22, 2013 - 21:11 GMT

Merck Receives Breakthrough Therapy Designation for MK-5172/MK-8742, an Investigational Oral Combination Regimen for the Treatment ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has granted MK-5172/MK-8742 Breakthrough Therapy designation for treatment of …

Distribution channels: Companies

Published on October 16, 2013 - 13:52 GMT

Merck Presents New Pharmacokinetic Data on ISENTRESS® (raltegravir) at 14th European AIDS Conference

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, is presenting pharmacokinetic data this week on investigational formulations of a once daily (QD) dose of ISENTRESS at the 14th European AIDS …

Distribution channels: Companies

Published on October 16, 2013 - 13:04 GMT

Merck Presents New Pharmacokinetic Data on ISENTRESS® (raltegravir) at 14th European AIDS Conference

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, is presenting pharmacokinetic data this week on investigational formulations of a once daily (QD) dose of ISENTRESS at the 14th European AIDS …

Distribution channels: Companies

Published on October 14, 2013 - 22:47 GMT

Results of Phase II PRECEDENT Trial for Investigational Folate Receptor Therapy Vintafolide in Patients with Platinum-Resistant ...

WHITEHOUSE STATION N.J., WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, (NYSE: MRK) and Endocyte, Inc. (NASDAQ: ECYT) today announced the online publication of results from the randomized Phase II PRECEDENT …

Distribution channels: Companies

Published on October 14, 2013 - 21:41 GMT

Results of Phase II PRECEDENT Trial for Investigational Folate Receptor Therapy Vintafolide in Patients with Platinum-Resistant ...

WHITEHOUSE STATION N.J., WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, (NYSE: MRK) and Endocyte, Inc. (NASDAQ: ECYT) today announced the online publication of results from the randomized Phase II PRECEDENT …

Distribution channels: Companies

Published on October 8, 2013 - 14:32 GMT

Results from a New Poll: Many Adults Aged 60-Plus Plan to Take Steps to Avoid Flu but Not Other Potentially Preventable Diseases ...

Flu is at the top of the list of diseases older adults plan to ask about, according to results from a new Harris Interactive consumer awareness survey, sponsored by Merck (NYSE: MRK), known as MSD outside the United States and Canada. Most (68 percent) of …

Distribution channels: Companies

Published on October 1, 2013 - 18:26 GMT

Interim Data for Merck’s MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Previously Treated Patients with Non-Small Cell ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, confirmed today that interim data from the company’s Phase IB expansion study (PN 001) evaluating the efficacy and safety of *MK-3475 in …

Distribution channels: Companies

Published on October 1, 2013 - 17:11 GMT

Interim Data for Merck’s MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Previously Treated Patients with Non-Small Cell ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, confirmed today that interim data from the company’s Phase IB expansion study (PN 001) evaluating the efficacy and safety of *MK-3475 in …

Distribution channels: Companies

Published on October 1, 2013 - 15:06 GMT

Data from Merck’s Investigational Hepatitis C Treatment Portfolio to be Presented at the 64th American Association for the Study ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of data from studies evaluating the company’s investigational oral chronic hepatitis C virus (HCV) treatments …

Distribution channels: Companies

Published on October 1, 2013 - 14:17 GMT

Data from Merck’s Investigational Hepatitis C Treatment Portfolio to be Presented at the 64th American Association for the Study ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of data from studies evaluating the company’s investigational oral chronic hepatitis C virus (HCV) treatments …

Distribution channels: Companies

Published on October 1, 2013 - 13:01 GMT

Merck Announces Global Initiative to Sharpen Commercial and R&D Focus

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced a global initiative to sharpen its commercial and research and development (RD) focus. The multi-year initiative will enable …

Distribution channels: Companies

Published on October 1, 2013 - 13:01 GMT

Merck Updates Plans for Headquarters Move in New Jersey

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced plans to move its global headquarters from Whitehouse Station, N.J., to its existing facilities in Kenilworth, N.J. The company …

Distribution channels: Companies

Published on September 27, 2013 - 13:34 GMT

Merck to Hold Third-Quarter 2013 Sales and Earnings Conference Call on October 28

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2013 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Monday, Oct. …

Distribution channels: Companies

Published on September 25, 2013 - 13:15 GMT

OXYTROL® FOR WOMEN, the First Over-the-Counter Treatment for Overactive Bladder in Women, Now Available Nationwide

Merck Consumer Care, the makers of OXYTROL FOR WOMEN, announced today that the more than 20 million women suffering from overactive bladder (OAB) can now gain better control of their condition with a visit to the feminine care aisle at their local retailer …

Distribution channels: Companies

Published on September 23, 2013 - 13:52 GMT

Merck Receives Complete Response Letter for Investigational Medicine Sugammadex Sodium Injection

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the company has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission …

Distribution channels: Companies

Published on September 23, 2013 - 13:39 GMT

Merck Receives Complete Response Letter for Investigational Medicine Sugammadex Sodium Injection

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the company has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission …

Distribution channels: Companies

Published on September 17, 2013 - 18:52 GMT

Merck Named To 2013 Working Mother 100 Best Companies

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that it has been named as one of the Working Mother 100 Best Companies for 2013. Honored on the list for the 26th year, Merck is among the 100 companies recognized for …

Distribution channels: Companies

Merck Press Releases Distributed by EIN Presswire